Trial reportBMC anesthesiology2025
Efficacy and safety of remimazolam for induction and maintenance of general anesthesia in day surgery: a randomized controlled non-inferiority clinical trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of Remimazolam and Propofol for Anesthesia Management in Liver Cancer Patients Undergoing Percutaneous Radiofrequency Ablation: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- The Influence of Remimazolam versus Propofol on Quality of Emergence and Sleep in Elderly Patients After Spinal Surgery: A Non-Randomized Observational Study.Drug design, development and therapy · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRemimazolam is a novel ultrashort-acting benzodiazepine anesthetic demonstrated to be safe and effective for painless gastroscopy and bronchoscopy. However, research on the application of remimazolam in general anesthesia for short day surgery is relatively limited. This study aimed to evaluate the efficacy and safety of remimazolam for both the induction and maintenance of general anesthesia in short day surgery.
methodOne hundred patients who underwent elective surgery were randomly divided into two groups: the Propofol group and the Remimazolam group. The primary outcomes consisted of the rates of successful anesthesia, defined by the absence of intraoperative awareness, the need for additional sedatives, and any involuntary limb movements, along with the incidence of life-threatening adverse events. The secondary outcomes included mean arterial pressure (MAP), heart rate (HR), time to loss of consciousness (LOC), injection pain, administration of vasopressors, time to extubation and eye opening, length of PACU stay, VAS score, and occurrence of postoperative adverse reactions.
resultsThe anesthesia efficacy was 100% in both groups. However, the time to LOC in the Propofol group was shorter than that in the Remimazolam group (P < 0.01). Compared with the Remimazolam group, the Propofol group presented a significant decrease in HR and MAP at the time of LOC (P < 0.05) and a significant decrease in MAP at 30 min after the start of surgery (P < 0.05). The use of vasopressors and the incidence of injection pain were significantly greater in the Propofol group than in the Remimazolam group (P < 0.05).
conclusionCompared with propofol, when the antagonist flumazenil is not used, remimazolam is not inferior to propofol in terms of safety and efficacy in the induction and maintenance of anesthesia for short daytime surgeries, and it does not cause delayed discharge of patients or increase postoperative adverse reactions.
trial registrationThis trial was registered with the Chinese Clinical Trial Registry (ChiCTR2400088335, registration date: August 15, 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.